

NERVIANO MEDICAL SCIENCES

Tiziano Lazzaretti Appointed as CFO to Drive Financial Strategy at NMS Srl

NERVIANO, IT and BOSTON, Mass, November 2, 2023 - Nerviano Medical Sciences S.r.l., a part of NMS Group S.p.A. (NMS Group) and Nerviano Medical Sciences, Inc., a wholly owned subsidiary of NMS Group, focused on the discovery and early development of oncology drugs and the largest oncological R&D company in Italy, announced today the appointment of Tiziano Lazzaretti as its new Chief Financial Officer (CFO). Tiziano brings a wealth of leadership experience in corporate strategies, finance, and governance, acquired across diverse industries, including chemicals, pharmaceuticals and biotechnology sectors.

With a proven track record of scaling business operations, managing cross-functional projects, and securing transformative deals, Tiziano is well-prepared to support NMS Group into its next phase of growth. His expertise in strategic and business turnarounds, M&A transactions, and preparing companies for listing on stock exchanges, including Nasdaq and the London Stock Exchange, positions him as a key strategic partner to the executive leadership team.

Before joining NMS Group, Tiziano held executive positions at Accenture, Snia Spa, Walgreen Boots, Teva, and various British-American biotech public listed start-ups, culminating in his last role as CFO of a Swiss-based biotech platform company.

"We are delighted to welcome Tiziano to our team," said Hugues Dolgos, Pharm.D., Chief Executive Officer. "Tiziano's extensive financial acumen and deep understanding of the biotech sector make him the ideal candidate to help us achieve our strategic objectives and drive our mission to improve patient health through groundbreaking innovations."

"I am extremely honored and privileged to be appointed Chief Financial Officer and grateful for the trust and support from the management team and the Board," said Tiziano. "I am thrilled to join the company at a significant inflection point and highly committed to driving a game-changing development process, with the support of a high-standing professional team."

As CFO, Tiziano will oversee all financial functions, including budgeting, financial reporting, investment strategy, and capital allocation. His leadership will be instrumental in supporting NMS's ongoing research and development efforts to advance our pipeline, as well as our commitment to delivering cutting-edge solutions that have a positive impact on patient lives. NMS Srl looks forward to leveraging Tiziano's expertise and leadership to achieve new milestones and drive financial excellence.

About Nerviano Medical Sciences

[Nerviano Medical Sciences](https://www.nervianoms.com) S.r.l. (NMS Srl) is focused on discovery and clinical development of small molecule NCEs for oncology. We take innovative approaches on novel mechanisms of action and drug targets to bring first- and best-in-class personalized medicines to cancer patients. Our current pipeline consists of NCEs, which all originate from our well validated kinase platform that span from early preclinical to clinical stage projects and which are being developed both in house and with partners.

NERVIANO MEDICAL SCIENCES

NMS Srl combines the flexibility of a biotech with the quality of a big pharma. Here, an experienced management team leads a highly skilled staff of professionals with global vision and a broad range of expertise in research, drug discovery and clinical development. We cover the whole range of additional aspects of drug development through the NMS Group affiliate companies, Accelera (AdMet) and NerPharMa (manufacturing).

A key strength is our industrially renowned kinase inhibitor drug discovery platform which comprises an ever-evolving chemical collection with broad intellectual property coverage, discovery know-how and technologies which enabled us to out-license IP rights on recently approved innovative medicines such as encorafenib and entrectinib.

We collaborate with academia and clinical investigators as well as with industrial partners worldwide to advance our programs from early discovery to clinical development of new drugs. We seek further strategic collaborations to develop and commercialize our products in different territories as well as in-licensing opportunities of promising assets for clinical development.

About NMS Group

[NMS Group](#) is the largest oncological R&D company in Italy. With more than 400 employees of whom more than half are highly educated individuals dedicated to innovative research, development and manufacturing. The NMS kinase inhibitor discovery platform as well as the antibody-conjugating payload platform are the driving forces of the group's innovation, securing global recognition of NMS in personalized therapy. Recently entrectinib, originally discovered by NMS, is a targeted kinase inhibitor to treat NTRK1/2/3 and ROS1 dependent solid tumors that was licensed to Ignyta, now a member of the Roche Group, gained approvals for commercialization in all major markets. This is further evident of the competitiveness of the drug discovery platform of NMS Group.

NMS Group has three subsidiaries. NMS S.r.l. is a FIC / BIC focused drug research and development company with a robust pipeline of more than a dozen of anti-cancer projects, and three of the projects are currently in early clinical development. The other two subsidiaries are Accelera, which is a preclinical CRO company, and NerPharMa which manufactures API and drug product supporting clinical developments and commercialization.

Media Relations: sidney.dung@nmsgroup.it